LOS ANGELES, Sept. 12, 2012 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BioSig), a medical device company developing unique clinical solutions for the electrophysiology market, announced that Dr. Asher Holzer has joined the Company as Chief Scientific Officer.
Dr. Holzer, a 30 year medical device industry veteran and innovator in cardiac technologies, has held a variety of senior executive positions during his career, the most recent as Chairman and President of InspireMD , a novel stent technology company.
Dr. Holzer brings to BioSig unique experience in the development of advanced medical devices for the electrophysiology market. He was the worldwide product manager of the CARTO™ System for Biosense Webster, a Johnson & Johnson company, taking the product from development to worldwide sales.
Kenneth L. Londoner, co-founder, Chairman, and Chief Executive Officer of BioSig Technologies, Inc. commented, "We are excited to have someone of Asher's skill and experience join forces with our team. Asher is a proven medical technologist with a great track record in bringing medical technologies to market. His unique understanding of EP technology and the marketplace will strengthen our innovation, product and IP portfolio."
Asher Holzer added, "Ken and I worked very closely at InspireMD and I am looking forward to collaborating with him and the technology team at BioSig. The EP market is constantly looking for innovation and I believe BioSig has potential to make an important contribution to improving arrhythmia patient care."
About BioSig Technologies, Inc.
BioSig Technologies, Inc. is a medical device company developing clinical solutions for the diagnosis and treatment of abnormal heart rhythms (arrhythmias). BioSig's PURE EP™ platform is designed to assist electrophysiologists during cardiac ablation. PURE EP™ empowers clinicians to make crucial clinical decisions in real time by providing information unobtainable with any other equipment in the EP lab.
The BioSig Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14637